Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines
Abstract Primary effusion lymphoma (PEL) and a form of multicentric Castleman’s disease (MCD) are both caused by Kaposi sarcoma herpesvirus (KSHV). There is a critical need for improved therapies for these disorders. The IL-6/JAK/STAT3 pathway plays an important role in the pathogenesis of both PEL...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-54453-7 |
| _version_ | 1797274947236659200 |
|---|---|
| author | Yiquan Wu Victoria Wang Robert Yarchoan |
| author_facet | Yiquan Wu Victoria Wang Robert Yarchoan |
| author_sort | Yiquan Wu |
| collection | DOAJ |
| description | Abstract Primary effusion lymphoma (PEL) and a form of multicentric Castleman’s disease (MCD) are both caused by Kaposi sarcoma herpesvirus (KSHV). There is a critical need for improved therapies for these disorders. The IL-6/JAK/STAT3 pathway plays an important role in the pathogenesis of both PEL and KSHV-MCD. We explored the potential of JAK inhibitors for use in PEL and KSHV-MCD, and found that pacritinib was superior to others in inhibiting the growth of PEL cell lines. Pacritinib induced apoptosis in PEL cells and inhibited STAT3 and NF-κB activity as evidenced by reduced amount of phosphorylated moieties. Pacritinib also inhibits FLT3, IRAK1, and ROS1; studies utilizing other inhibitors of these targets revealed that only FLT3 inhibitors exhibited similar cell growth inhibitory effects. FLT3’s likely contribution to pacritinib’s cell growth inhibition was further demonstrated by siRNA knockdown of FLT3. RNA sequencing and RT-PCR showed that many key host genes including cyclins and IL-6 were downregulated by pacritinib, while KSHV genes were variably altered. Finally, pacritinib suppressed KSHV viral IL-6-induced human IL-6 and IL-10 production in peripheral blood mononuclear cells, which may model an important step in KSHV-MCD pathogenesis. These results suggest that pacritinib warrants testing for the treatment of KSHV-MCD and PEL. |
| first_indexed | 2024-03-07T15:06:23Z |
| format | Article |
| id | doaj.art-9ebccab469f24466b9f0e8fa9c64894f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:06:23Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-9ebccab469f24466b9f0e8fa9c64894f2024-03-05T18:53:49ZengNature PortfolioScientific Reports2045-23222024-02-0114111210.1038/s41598-024-54453-7Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokinesYiquan Wu0Victoria Wang1Robert Yarchoan2HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer InstituteHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer InstituteHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer InstituteAbstract Primary effusion lymphoma (PEL) and a form of multicentric Castleman’s disease (MCD) are both caused by Kaposi sarcoma herpesvirus (KSHV). There is a critical need for improved therapies for these disorders. The IL-6/JAK/STAT3 pathway plays an important role in the pathogenesis of both PEL and KSHV-MCD. We explored the potential of JAK inhibitors for use in PEL and KSHV-MCD, and found that pacritinib was superior to others in inhibiting the growth of PEL cell lines. Pacritinib induced apoptosis in PEL cells and inhibited STAT3 and NF-κB activity as evidenced by reduced amount of phosphorylated moieties. Pacritinib also inhibits FLT3, IRAK1, and ROS1; studies utilizing other inhibitors of these targets revealed that only FLT3 inhibitors exhibited similar cell growth inhibitory effects. FLT3’s likely contribution to pacritinib’s cell growth inhibition was further demonstrated by siRNA knockdown of FLT3. RNA sequencing and RT-PCR showed that many key host genes including cyclins and IL-6 were downregulated by pacritinib, while KSHV genes were variably altered. Finally, pacritinib suppressed KSHV viral IL-6-induced human IL-6 and IL-10 production in peripheral blood mononuclear cells, which may model an important step in KSHV-MCD pathogenesis. These results suggest that pacritinib warrants testing for the treatment of KSHV-MCD and PEL.https://doi.org/10.1038/s41598-024-54453-7 |
| spellingShingle | Yiquan Wu Victoria Wang Robert Yarchoan Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines Scientific Reports |
| title | Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines |
| title_full | Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines |
| title_fullStr | Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines |
| title_full_unstemmed | Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines |
| title_short | Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines |
| title_sort | pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin 6 induced cytokines |
| url | https://doi.org/10.1038/s41598-024-54453-7 |
| work_keys_str_mv | AT yiquanwu pacritinibinhibitsproliferationofprimaryeffusionlymphomacellsandproductionofviralinterleukin6inducedcytokines AT victoriawang pacritinibinhibitsproliferationofprimaryeffusionlymphomacellsandproductionofviralinterleukin6inducedcytokines AT robertyarchoan pacritinibinhibitsproliferationofprimaryeffusionlymphomacellsandproductionofviralinterleukin6inducedcytokines |